

Published in final edited form as:

*Clin Infect Dis.* 2008 October 15; 47(8): 1114–1115. doi:10.1086/592124.

## MTCT risk is increased among HIV-infected pregnant women with positive syphilis serology in Ukraine

Claire Thorne<sup>1</sup>, Ruslan Malyuta<sup>2</sup>, Igor Semenenko<sup>2</sup>, Tatyana Pilipenko<sup>2</sup>, Andrej Stelmah<sup>3</sup>, Svetlana Posokhova<sup>4</sup>, and Marie-Louise Newell<sup>1,5</sup>

<sup>1</sup>MRC Centre of Epidemiology for Child Health, UCL Institute of Child Health, University College London, UK

<sup>2</sup>Prevention of Perinatal AIDS Initiative, Odessa, Ukraine

<sup>3</sup>AIDS Centre of Crimea, Simferopol, Ukraine

<sup>4</sup>Department of Obstetrics and Gynecology, Odessa Regional Hospital, Odessa, Ukraine

<sup>5</sup>Africa Centre for Health and Population Studies, University of KwaZulu Natal, South Africa

---

To the Editor,

Although syphilis coinfection is a known risk factor for heterosexual transmission of HIV [1,2], its role in mother-to-child transmission (MTCT) is unclear [3-5]. We investigated the impact of maternal positive syphilis serology on MTCT in the Ukrainian sites of the European Collaborative Study, a cohort study of HIV-infected pregnant women and their children; full methods are described elsewhere [6]. The mother-child pairs (MCPs) in this analysis came from a nested sub-study of sexually transmitted infections (STI) [7]: for MCPs enrolled from January 2003 to October 2005, STI test results were extracted from antenatal records and linked to the prospective ECS database; subsequently, one centre started prospective collection of all antenatal STI test results and MCPs enrolled here from October 2005 were also included. Antenatal serological screening was performed with non-treponemal tests at pregnancy registration and repeated in the third trimester, with confirmatory testing using treponemal tests, according to national policy. Infected women and their infants were treated with penicillin.

Logistic regression was used to investigate MTCT risk factors. Infants with persistence of HIV antibody beyond 18 months of age and/or a positive HIV PCR test were considered HIV-infected; infants HIV antibody-negative and/or with two negative PCRs were classified as uninfected [6]. Variables considered in the multivariable model were maternal syphilis serology, antiretroviral prophylaxis, elective Caesarean section delivery and premature delivery (<37 completed gestational weeks) and were retained based on Akaike's Information Criterion [6]

There were 521 MCPs with known infant HIV infection status. All women were born in Ukraine, median maternal age was 25.0 years (range, 16.1-43.4) and 66% (n=346) were nulliparous. Injecting drug use (IDU) history was reported by 20% (105/516) women; a further 210 (40%) women reported an IDU sexual partner. Overall, 3.5% (95% CI 2.1-5.4)

---

Corresponding author: Dr Claire Thorne, MRC Centre of Epidemiology for Child Health, UCL Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK Tel: +44 2079052105 Fax: +44 2078138145 c.thorne@ich.ucl.ac.uk.

### Collaborators

T. Pilipenko, Y. Khomout (Perinatal Prevention of AIDS Initiative, Odessa), Dr S Posokhova, Dr T Kaleeva, Dr. A. Shelyag, Dr. S. Servetsky (Odessa), Dr A. Stelmah, Dr. G. Kiseleva, Dr O. A. Zalata (Crimean Republic).

pregnant women had positive syphilis serology, increasing to 5.7% (6/105, 95%CI 2.1-12.0) among women with IDU history (a non-significant difference).

Antenatal CD4 counts were available for 163 (31%) women only, due to limited laboratory capacity. Median CD4 count was 514 cells/mm<sup>3</sup> (IQR, 350-700) overall, with no difference by syphilis status. The HIV MTCT rate was 5.8% (30/521, 95% CI 3.9-8.1%) overall and was significantly higher among women seropositive for syphilis ( $\chi^2=6.4$ ,  $p=0.011$ ) (Table). Positive antenatal syphilis serology was associated with a five-fold increased MTCT risk univariably and a nearly 4.5-fold increased risk in the adjusted model (Table).

Our study provides the first evidence of an association between maternal syphilis and MTCT risk in an Eastern European setting. A limitation is the lack of maternal HIV RNA quantification in our population, which prevented us from adjusting for this important risk factor for MTCT [6]. However, in a study in Malawi, maternal syphilis coinfection was associated with a 2.6-fold increased risk of in utero HIV transmission univariably and 2.7-fold increased risk independent of maternal viral load [3]. Elimination of congenital syphilis and “virtual elimination” of HIV transmission to infants are key public health goals [8-9], and our findings underscore the need for integration of antenatal syphilis screening and treatment programmes with PMTCT programmes.

## Acknowledgments

The ECS is a coordination action of the European Commission (PENTA/ECS 018865). Claire Thorne is supported by a Wellcome Trust Research Career Development Fellowship. This work was undertaken at GOSH/UCL Institute of Child Health which received a proportion of funding from the UK Department of Health's NIHR Biomedical Research Centres funding scheme. The Centre for Paediatric Epidemiology and Biostatistics also benefits from funding support from the Medical Research Council in its capacity as the MRC Centre of Epidemiology for Child Health.

We would like to acknowledge the contribution of Dr Megan Landes to the coordination of the nested STI sub-study

## References

1. Wasserheit J. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. *Sexually Transmitted Diseases*. 1992; 19:61–77. [PubMed: 1595015]
2. Hanson, et al. Assessment of sexually transmitted diseases as risk factors for HIV seroconversion in a New Orleans sexually transmitted disease clinic, 1990-1998. *Annals of Epidemiology*. 2005; 15:13–20. [PubMed: 15571989]
3. Mwapasa V, Rogerson SJ, Kwiek JJ, et al. Maternal syphilis infection is associated with increased risk of mother-to-child transmission of HIV in Malawi. *AIDS*. 2006; 20:1869–77. [PubMed: 16954728]
4. Cowan FM, Humphrey JH, Ntozini R, Mutasa K, Morrow R, Iliff P. Maternal Herpes simplex virus type 2 infection, syphilis and risk of intra-partum transmission of HIV-1: results of a case control study. *AIDS*. 2008; 22:193–201. [PubMed: 18097221]
5. Lee MJ, Hallmark RJ, Frenkel LM, Del Priore G. Maternal syphilis and vertical perinatal transmission of human immunodeficiency virus type-1 infection. *Int J Gynaecol Obstet*. 1998; 63:247–52. [PubMed: 9989893]
6. European Collaborative Study. The mother-to-child HIV transmission epidemic in Europe: established in the West and evolving in the East. *AIDS*. 2006; 20:1419–1427. [PubMed: 16791017]
7. Landes M, Thorne C, Barlow P, et al. Prevalence of sexually transmitted infections in HIV-1 infected pregnant women in Europe. *Eur J Epidemiol*. 2007; 22:925–36. [PubMed: 17926135]
8. World Health Organization. The Global elimination of congenital syphilis: rationale and strategy for action. WHO; Geneva: 2007.

9. Interagency Task Team on Prevention of HIV infection in pregnant women. Towards universal access for women, infants and young children and eliminating HIV and AIDS among children. WHO; Geneva: 2007. Guidance on global scale-up of the prevention of mother-to-child transmission of HIV.

**Table**  
**Unadjusted MTCT rates and logistic regression analyses of risk of mother-to-child transmission (n=521)**

|   | Unadjusted MTCT rate | OR (95% CI)      | p value | Adjusted OR (95% CI) | p value |
|---|----------------------|------------------|---------|----------------------|---------|
| Maternal syphilis serology              |                      |                  |         |                      |         |
| Negative                                | 5.2% (26/503)        | 1.00             |         | 1.00                 |         |
| Positive                                | 22.2% (4/18)         | 5.24 (16.1-17.0) | p=0.006 | 4.43 (1.31-15.0)     | p=0.02  |
| Antenatal / intrapartum ARV prophylaxis |                      |                  |         |                      |         |
| None                                    | 23.1% (3/13)         | 1.00             |         | 1.00                 |         |
| Single dose nevirapine only             | 11.1% (8/72)         | 0.42 (0.09-1.84) | p=0.25  | 0.41 (0.09-1.88)     | p=0.25  |
| Antenatal ARV prophylaxis               | 4.4% (19/436)        | 0.15 (0.04-0.60) | p=0.007 | 0.19 (0.05-0.80)     | p=0.02  |
| Premature delivery                      |                      |                  |         |                      |         |
| No                                      | 5.1% (25/489)        | 1.00             |         | 1.00                 |         |
| Yes                                     | 15.6% (5/32)         | 3.44 (1.22-9.68) | p=0.02  | 2.21 (0.72-6.83)     | p=0.17  |
| Elective Caesarean section delivery     |                      |                  |         |                      |         |
| No                                      | 8.4% (19/226)        | 1.00             |         | -                    |         |
| Yes                                     | 3.7% (11/295)        | 0.42 (0.20-0.91) | p=0.03  |                      |         |

OR, odds ratio; ARV, antiretroviral